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Introduction: In the past decade, major progress has been made toward 
personalized medical treatment of non–small-cell lung cancer (NSCLC) 
through the discovery of epithelial growth factor receptor (EGFR) muta-
tions. However, mutation analysis takes extra time and additional costs 
in the diagnostic evaluation of lung cancer patients. It has been hypoth-
esized that EGFR mutations are restricted to terminal respiratory unit 
-type adenocarcinoma expressing thyroid transcription factor-1 (official 
symbol NKX2-1) as determined by immunohistochemistry. The aim of 
the current study is to evaluate the potential of NKX2-1 immunohisto-
chemistry as a prescreening test for EGFR mutation analysis.
Methods: From 2004 to December 2010, 810 consecutive NSCLC 
tumor specimens were tested for EGFR mutations in a routine diag-
nostic procedure. Immunohistochemistry for NKX2-1 was per-
formed (clone 8G7G3/1 [Dako]) and the results were compared with 
tumor EGFR-mutation status and clinicopathological characteristics.
Results: EGFR mutations were detected in 114 specimens (14%). 
NKX2-1 expression was present in 68%. In the cases with EGFR 
mutation, NKX2-1 staining was positive in 92%. NKX2-1 immuno-
histochemical (IHC) staining was significantly associated with the 
presence of EGFR mutations (p = 5.3 × 10−10). NKX2-1 increased the 
negative predictive value in NSCLC to more than 95%.
Conclusions: In case of a negative NKX2-1 IHC staining, and only if 
clinically urgent, the high negative predictive value of more than 95% 
for EGFR mutations is a suitable temporary surrogate marker for the 
choice of starting with chemotherapy. In case of positive NKX2-1 
IHC, the best strategy is to wait for the outcome of EGFR-mutation 
analysis and then choose the appropriate treatment.
 Key Words: TTF-1, NKX2-1, Lung cancer, EGFR-mutation analy-
sis, Treatment.
(J Thorac Oncol. 2012;7: 1522–1527)
In the past decade, major progress has been made toward personalized treatment of non–small-cell lung cancer 
(NSCLC). The first breakthrough was the discovery of epi-
thelial growth factor receptor (EGFR) mutations. The second 
major improvement was the discovery of tumor reaction on 
anaplastic lymphoma kinase (ALK) inhibitors in patients with 
ALK rearrangements.1
The outcome of EGFR-mutation analysis has a predic-
tive value for the treatment with EGFR-TKIs. The tumors with 
activating EGFR mutations react better and those without 
EGFR mutation react worse on EGFR TKI than conventional 
chemotherapy.2–5 Mutation analysis takes time, varying in 
daily practice from a few days to weeks, partly depending on 
access to a reliable test in the direct environment. Postponing a 
decision on the choice of treatment often collides with clinical 
urgency. A fast prescreening test to select for cases to undergo 
mutation testing might solve the postponement dilemma. The 
clinical factors associated with the presence of EGFR muta-
tions are: nonsmoking status, female sex, and adenocarcinoma 
subtype. If one or more of these clinical parameters is present, 
the chance of having an EGFR mutation is higher, but lack-
ing these characteristics does not exclude the presence of an 
EGFR mutation. On the basis of the separate clinical criterion 
mentioned above, respectively 33%, 30%, and 19% of tumors 
with EGFR mutations would be missed in a white population.6 
Currently, the acceptable percentage of EGFR mutations that 
can be missed in the treatment of lung cancer is a matter of 
debate. If it is acceptable to miss 1% of tumors with EGFR 
mutation, then these parameters are clearly insufficient for the 
selection of patients with EGFR mutation.
EGFR-mutation specific antibodies have been developed 
against a 15 base pair deletion in exon 19 and a L858R point 
mutation in exon 21. Currently, they are not recommended for 
predictive testing, as the sensitivity is not high enough, taking 
the other relevant mutations into account, especially exon 19 
deletions of other base pair lengths.7–13
Yatabe et al.14 suggested that the presence of an EGFR 
mutation is specific for terminal respiratory unit -type 
adenocarcinoma, characterized by the expression of thyroid 
transcription factor-1 (TTF-1). TTF-1 is a homeodomain-
containing protein closely related to members of the Drosophila 
NK-2 gene family and its official full name is NK-2 homeobox 1 
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(NKX2-1).15,16 NKX2-1 is also known as NXK2A, TTF-1, 
TTF1, TITF1, thyroid-specific enhancer-binding protein, and 
benign chorea17 The name TTF-1 is most commonly used, but 
it may be confused with the official symbol for transcription 
termination factor, RNA polymerase I (TTF1). NKX2-1 
regulates transcription of genes specific for the thyroid, lung, and 
diencephalon.15,17–25
Expression of NKX2-1 is required for the proper devel-
opment of the thyroid and lungs.26,27 NKX2-1 is expressed in 
the lungs in type-II-pneumocytes and nonciliated bronchiolar 
epithelial cells and it has a binding site in the promoter region 
of surfactants and Clara cell secretory proteins.28–32 NKX2-1 
plays an active role in sustaining lung cancer.33–36
In NSCLC, expression of NKX2-1 is retained, though 
it varies with the histological subtype. Results of immuno-
histochemistry also depend on the staining method used.37 In 
adenocarcinoma (ACC), approximately 75% (range, 58–84%) 
of tumors are NKX2-1 positive.38–52 Mucinous ACCs tend to 
show NKX2-1 expression less frequently (0–21%).39,53–55 Most 
studies on squamous cell lung carcinomas show no expres-
sion of NXK2-1,39,42,44,45,48,52 although others show expression 
in 5% to 38% of squamous lung carcinoma specimens.40,47,51 
Expression of NKX2-1 in pulmonary non-neuroendocrine 
large cell carcinoma is reported in 0 to 50%.42,44,51,56 In pulmo-
nary neuroendocrine large cell carcinoma expression in 57% 
to 75% of tumors is reported.56,57
NKX2-1 is determined by immunohistochemistry, a 
test much faster than mutation analysis. In several articles, 
NKX2-1 expression was found in 93% to 96% of tumors with 
EGFR mutations.14,58,59 This may generate the hypothesis that 
NKX2-1 can be used to preselect patients for a temporary 
treatment decision. In case of negativity for NKX2-1 and a 
need for urgent treatment, start conventional chemotherapy, 
ahead of the outcome of EGFR-mutation analysis. In case of 
positivity for NKX2-1, wait for the results of EGFR-mutation 
analysis before starting treatment.
The aim of this study is to examine whether NKX2-1 
immunohistochemical (IHC) staining is a useful temporary 
surrogate marker for choice of treatment guidance in meta-
static NSCLC.
PATIENTS AND METHODS
A database was constructed of consecutive tumor speci-
mens of NSCLC patients (n = 810) referred for EGFR muta-
tion testing during the course of routine diagnostics from May 
2004 to December 2010 at the VU University Medical Center 
in Amsterdam. The decision for referral (i.e., selection of 
patients for mutation analysis) was made by the treating local 
or referring pulmonologist/pathologist. The submitted histo-
logic diagnosis was performed according to the World Health 
Organization classification.60 All samples were used in com-
pliance with the respective institutional ethical regulations.
Immunohistochemistry
NKX2-1IHC was carried out as described previously.61 
For NKX2-1IHC clone 8G7G3/1 (Dako) was used.38 In every 
IHC staining procedure, a negative and an external posi-
tive control were used. Staining intensity was scored, using 
a method modified from a method described by Ruschoff et 
al.,62 with intensity ranging from 0 to 3: 3 = strongly posi-
tive, with microscope objectives 2.5−4×; 2 = moderate with 
microscope objectives 10−20×; 0 = no nuclear staining, 1 = 
weak with microscope objective 40×. For each intensity, the 
FIGURE 1.  Examples of NKX2-1 
immunohistochemistry. (A), Strong 
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percentage of positive tumor cells was examined, resulting in 
an H-score, consisting of the sum of the each intensity multi-
plied by the percentage of positive tumor cells.63  Specimens 
with scores of 30 or more were considered positive for NKX2-
1. Examples are shown in Fig. 1.
EGFR Mutation Analysis
Mutation analysis was performed as described previ-
ously.64–66 Exons 19 to 21 were examined. Initially, poly-
merase chain reaction (PCR)-sequencing was used, and since 
2008 high-resolution melting (HRM) was used as screening. 
Abnormalities were examined by PCR-sequencing.
Statistical Analysis
The correlation between EGFR mutations and NKX2-1 
positivity was assessed using the χ2 test. Differences between 
groups were compared with the nonparametric Mann-Whitney 
test for continuous variables and with the binomial test for 
two proportions for dichotomous variables. A p value less than 
0.05 was considered to be significant. All statistical analyses 
were performed using SPSS 15.0.
RESULTS
Clinical characteristics for the outcome of EGFR-
mutation analysis are shown in Table 1. A series of 810 tumor 
specimens of an equal number of patients with NSCLC were 
evaluated for EGFR-mutation status, divided over biopsies (n 
= 594), resections (n = 162), and cytological samples (n = 54). 
The median age for women (n = 399) was 63 years (range, 
25–91), slightly lower than the median age of men (n = 411) 
(66 years; range, 21–87) (p value 3.1 × 10−6). Overall, EGFR 
mutations were detected in 114 specimens (14%).
NKX2-1 expression was available in 797 cases (98%) 
(see Table 1), in which 68% of the cases was IHC positive for 
NKX2-1 and 32% negative. In the EGFR-mutation positive 
cases 92% were positive for NKX2-1 and 8% negative.
NKX2-1 IHC staining was strongly associated with the 
presence of EGFR mutations (p = 5.3 × 10−10). Seventy-nine 
percent of the ACCs was NKX2-1 positive. The probability of 
an EGFR mutation in ACCs was 20%. The probability of the 
absence of EGFR mutations in ACCs is 80% and increases to 
96% for NKX2-1 negative ACCs. Likewise, EGFR mutations 
are not detected in 93% of non-ACC histology and in 96% of 
this histological group negative for NKX2-1 expression. Thus, 
the negative predictive value of NKX2-1 is more than 95% in 
NSCLC.
From the 17 EGFR mutated tumors with the histologic 
category other the distribution was as follows: 14 cases were 
NSCLC-not otherwise specified. one large cell neuroendo-
crine carcinoma, one squamous cell carcinoma, and one ade-
nosquamous carcinoma.
From the 162 resections, 27 (16.7%) were EGFR 
mutated, all of which were TTF1 positive. In contrast to the 
593 biopsies, 79 (13.3%) were EGFR mutated; of these, 
eight (10.1%) were TTF1 negative. This difference was not 
significant (p = 0.11). Of the 54 cytology specimens eight 
(14.8%) were EGFR mutated of which one (12.5%) was TTF1 
negative.
DISCUSSION
This study supports the strong concordance between 
NKX2-1–positive NSCLC and the presence of EGFR muta-
tions: only 8% (9 of 114) of EGFR mutations are found 
among NKX2-1–negative NSCLC cases. In case of negative 
NKX2-1, the odds that an EGFR mutation will be detected 
are one in 25. If treatment is urgent for clinical reasons, the 
negative predictive value of NKX2-1 expression of more than 
95% may be used as a surrogate marker to choose to start with 
conventional chemotherapy. If starting treatment is not urgent, 
the results of the EGFR-mutation analysis should be awaited, 
even if NKX2-1 IHC is negative. In case NKX2-1 IHC is 
positive, this outcome has not sufficient predictive value for 
EGFR mutations to use it for a preliminary choice of treat-
ment. Therefore, in all NKX2-1 IHC positive cases the results 
of the EGFR-mutation analysis should be awaited to be able to 
choose appropriate treatment.
The advantage of NKX2-1 IHC staining in selecting 
patients for therapy is that the result can be known in 3 
hours, the procedure is available in all or most pathology 
laboratories, and it has acceptable costs. The time span of 
mutation analysis is dependent on several factors: (1) In 








 Male 37 (9.0%) 346 (84.2%) 28 (6.8%) 411 2.1.10–5
 Female 77 (19.3%) 294 (73.7%) 28 (7.0%) 399 —
Histology
 Adeno 96 (18.3%) 394 (74.9%) 36 (6.8%) 526 3.0.10–6
 Other 18 (6.3%) 246 (86.6%) 20 (7.0%) 284 —
NKX2-1
 Positive 105 (19.4%) 403 (74.5%) 33 (6.1%) 541 2.6.10–9
 Negative 9 (3.5%) 228 (89.1%) 19 (7.4%) 256 —
 Unknown 0 (0.0%) 9 (69.2%) 4 (30.8%) 13 —
Histology divided in adenocarcinoma and other histological subtypes (Other).EGFR, epidermal growth factor receptor; NKX2-1, NK-2 homeobox 1.
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optimal organizations, mutation analysis by means of DNA 
isolation (overnight) PCR-HRM, followed by sequencing in 
case of a (suggestive) melting difference to exclude single 
nucleotide polymorphisms, requires, in practice, 2 days after 
the block is cut. If HRM analysis does not need to confirmed, 
it takes 1 day; (2) If the possibility of mutation analysis is 
not available in the local laboratory, the specimen needs to 
be transported, which adds at least another day; (3) Mutation 
analysis after a learning curve is inconclusive in 4% of the 
analysis (data not shown). In those cases, new tumor material 
should be obtained, which requires a new invasive procedure. 
Moreover, for some patients, the symptoms are so severe 
that immediate treatment may be necessary. For others, in 
the time frame of EGFR-mutation analysis, a deterioration 
of the clinical condition may occur. Waiting for the start of 
treatment may also be a psychological burden for patients, 
especially when symptoms are severe or deterioration is 
noticed. Therefore, a rapid support for treatment decision 
may be an unmet clinical need.
However, the result of NKX2-1 IHC staining is not 
sufficient to exclude patients from mutation analysis. If only 
NKX2-1 positive specimens are referred for mutation analy-
sis, 8% of tumors with an EGFR mutation would have been 
missed. Other studies show similar results.14,58,59 This percent-
age is a better result than using a single clinical parameter 
(sex, smoking, or race) as the selection criteria, but it is still 
too high to exclude NKX2-1–negative specimens of NSCLC 
from mutation analysis.
In general, EGFR mutations in NSCLC are more fre-
quently found in patients from East Asia than in patients from 
America and Europe.67 Our results do not present numbers of 
prevalence in a white population, because there was a selection 
bias. In the first period of mutation analysis, clinical param-
eters were influencing selection: samples of Asian, nonsmok-
ing, female patients with ACC were tested. Later, all patients 
with ACCs were tested. In our study, several outcomes point 
at a selection bias. The number of ACCs is almost twice as 
high as specimens from other histology, whereas the incidence 
of ACCs is almost equal to squamous cell carcinomas. The 
number of female patients in our series was almost as high as 
male patients, whereas in 2008 in The Netherlands the inci-
dence ratio for NSCLC for male versus female patients was 
1.7:1. Unfortunately, the smoking status of the patients was 
not recorded in the database.
In our study, we used a commercially available mono-
clonal antibody against NKX2-1, clone 8G7G3/1, which is 
the most specific antibody available for this protein. Most 
samples examined for EGFR mutation analysis were obtained 
from biopsies, where an essential number was derived from 
metastatic sites and therefore, lack an internal positive control 
for NKX2-1. Routinely, for each staining procedure an exter-
nal positive control for NKX2-1 is used. In addition, two lung 
specimens showed a positive internal control, whereas the 
tumor was negative, indicating the quality of our staining pro-
cedure. Other antibodies, such as SPT24, are found to be more 
sensitive for NKX2-1.37 The use of a more sensitive antibody 
would decrease the percentage of NKX2-1 negative speci-
mens with EGFR mutation. Although we did not test this, it 
is likely that the negative predictive value for NKX2-1 might 
even be higher with SPT24, also supporting the proposed use 
of NKX2-1 IHC staining for the intermediate decision regard-
ing the initial treatment of patients with NSCLC.
CONCLUSION
The presence of an EGFR mutation is strongly related to 
NKX2-1 expressing NSCLC, supporting the terminal respira-
tory unit hypothesis. In case of a negative NKX2-1 IHC stain-
ing, and only if clinically urgent, the high negative predictive 
value of more than 95% for EGFR mutations is a suitable 
temporary surrogate marker for the choice of starting with 
chemotherapy. In case of positive NKX2-1 IHC, the best strat-
egy is to wait for the outcome of EGFR-mutation analysis and 
then choose the appropriate treatment.
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